ChromaDex takes Tru Niagen into Brazil with MyPharma2Go partnership
The partnership to conduct cross-border sales of Tru Niagen and Tru Niagen PRO in Brazil marks the brands first move into Latin America.
Tru Niagen, Tru Niagen PRO and Tru Niagen Stickpacks are now available for sale in the Brazilian market on several cross-border marketplaces including www.saudecelular.com.br, www.mypharma2go.com, www.mundihealth.com and through HCP in-person sales.
“We are pleased to work with MyPharma2Go to introduce the healthy aging benefits of Tru Niagen to Brazil,” said Rob Fried, CEO of ChromaDex. “This moment marks a milestone as we amplify global growth plans for Tru Niagen. We look forward to continuing our partnership with the wonderful MyPharma2Go team on this Brazil cross-border strategy.”
MyPharma2Go, an American company focused on Brazil and Latin America, developed a cross-border e-commerce platform that allows patients to have direct access to international medicines and supplements, and monitors the international shipping process from origin to delivery.
André Di Donato, CEO and Founder of MyPharma2Go, commented: “In the last five years, our cross-border business has impacted more than 30,000 health professionals and has served more than 240,000 patients throughout Brazil. Through our partnership with ChromaDex and Tru Niagen, we will ensure our premium service delivers the best global products to our customers in Brazil.”
In 2004, Dr Charles Brenner discovered that nicotinamide riboside (NR) is a potent precursor to nicotinamide adenine dinucleotide (NAD). NAD is an important cellular co-factor for improvement of mitochondrial performance and energy metabolism.
As organisms age, NAD levels drop, which leads to a decrease in mitochondrial health; this in turn leads to age-related health issues. By boosting NAD, NR may increase mitochondrial health and induce the creation of new mitochondria.
Niagen, ChromaDex’s branded nicotinamide riboside, has been shown to increase NAD+ levels safely and efficaciously in nine published human trials.
Niagen is supported by two successful NDI notifications (NDIN 882 in 2015 and NDIN 1062 in 2018), as well as a successful GRAS notification (GRN 635).
The ChromaDex External Research Program (CERPTM) reached over 250 material transfer agreements (MTAs) featuring Niagen and other proprietary ingredients.